What is Eureka Therapeutics?
Eureka Therapeutics, Inc. operates at the intersection of advanced biotechnology and oncology, specializing in the development of innovative platforms designed to target malignancies with high precision. By leveraging its proprietary E-ALPHA and ARTEMIS technologies, the company utilizes high-throughput screening and T cell therapy to address the complex challenges associated with solid tumors. As a clinical-stage entity, Eureka Therapeutics is strategically positioned to bridge the gap between laboratory discovery and patient-centric clinical applications, providing healthcare professionals with sophisticated tools to improve therapeutic outcomes for cancer patients globally.
How much funding has Eureka Therapeutics raised?
Eureka Therapeutics has raised a total of $133.2M across 5 funding rounds:
Series A
$1.2M
Series B
$6M
Series C
$21M
Series D
$60M
Series E
$45M
Series A (2007): $1.2M, investors not publicly disclosed
Series B (2008): $6M, investors not publicly disclosed
Series C (2014): $21M supported by Yuan Capital, Suma Capital, Majuven, Acorn Campus, and Harbinger Venture Capital
Series D (2018): $60M, investors not publicly disclosed
Series E (2020): $45M backed by Lyell Immunopharma
Key Investors in Eureka Therapeutics
Suma Capital
Suma Capital is an independently owned investment management firm that specializes in responsible and sustainable private markets investing, with a clear focus on generating positive economic, environmental, and social impact alongside financial returns.
Majuven
Majuven is an early and growth stage venture capital firm based in Singapore, focusing on disruptive trends in high tech sectors such as healthcare, financial services, and digital consumerism.
Acorn Campus
Acorn Campus Ventures is a venture fund with incubation facility and infrastructure, focusing on the wireless, semiconductor, photonics, communications, internet and life science fields.
What's next for Eureka Therapeutics?
With the recent capital injection, Eureka Therapeutics is poised to accelerate its clinical development pipeline and expand its operational footprint. The strategic focus will likely shift toward scaling the manufacturing capabilities of its T cell therapy platforms and advancing ongoing clinical trials. By maintaining a rigorous commitment to scientific excellence and leveraging its robust network of institutional backers, the company is well-positioned to navigate the regulatory landscape and move closer to delivering transformative cancer-specific treatments to the market. Future growth will be defined by the successful validation of its therapeutic candidates and the continued refinement of its proprietary technology stack.
See full Eureka Therapeutics company page
